Skip to main content

Table 1 Characteristics of patients with HA20

From: Expanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report

Patient no Family Gender Current age Age at onset Previous diagnosis Current diagnosis Previous treatment Current treatment
1 Family 1 F 14.1 years 7.0 years liver fibrosis
Hypothyroidism
SLE
Lupus nephritis
HA20 Prednisolone
MMF
Sodium levothyroxine
HCQ
Prednisolone
MMF
Sodium levothyroxine
HCQ
Etanercept
2 Family 1 M 5.1 years 2.5 years Crohn’s disease
IBD-RA
HA20 Prednisolone
5-AminoSalicylicAcid
MTX
Prednisolone
5-AminoSalicylicAcid
MTX
Etanercept
3 Family 1 M 38.2 years 7.0 years HA20   
4 Family 2 F 8.3 years 6.9 years JIA, CTD-ILD
MAS
HA20 Prednisolone
CSA
Diclofenac Sodium
Prednisolone
CSA
Diclofenac Sodium
Etanercept
  1. SLE Systemic lupus erythematosus, IBD-RA Inflammatory bowel disease-related arthritis, CTD-ILD Connective tissue disease-related interstitial lung disease, MAS Macrophage activation syndrome, HCQ Hydroxychloroquine, MTX Methotrexate, CSA Cyclosporine A